Chronic thromboembolic pulmonary hypertension: role of medical therapy

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F13%3A10195160" target="_blank" >RIV/00216208:11110/13:10195160 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1183/09031936.00201612" target="_blank" >http://dx.doi.org/10.1183/09031936.00201612</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1183/09031936.00201612" target="_blank" >10.1183/09031936.00201612</a>

Result language
angličtina
Original language name
Chronic thromboembolic pulmonary hypertension: role of medical therapy
Original language description
Chronic thromboembolic pulmonary hypertension (CTEPH) is a progressive disease with poor prognosis if not treated. The treatment of choice is surgery with pulmonary endarterectomy. However, a significant percentage of patients are deemed non-operable dueto distal distribution of the disease and arteriopathy in the non-occluded areas that is indistinguishable from pulmonary arterial hypertension (PAH). The overlap in clinical presentation, pathological features and pathogenesis between PAH and CTEPH provides a compelling rationale for exploring the efficacy of PAH-targeted therapies in CTEPH. These therapies are often considered for non-operable patients and are also used in operable patients as a bridge to surgery or as post-pulmonary endarterectomy therapy for persistent pulmonary hypertension, despite the fact they are not licensed for CTEPH. Two randomised clinical trials have been performed in non-operable CTEPH patients. The BENEFIT study, with the endothelin receptor antagonist
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FA - Cardiovascular diseases including cardio-surgery
OECD FORD branch
—

Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)